A Phase 2 interventional study of carfilzomib and carfilzomib in Multiple Myeloma, sponsored by Amgen. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-31.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 12th largest by enrollment, is one of 3 that started in 2007, is one of 50 in phase 2, and was the 2nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 10th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2007, is one of 10 in phase 2, and was the 6th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease Related
Subjects must have defined as one of the following:
Demographic
Laboratory
Absolute neutrophil count > 1,000/mm3, hemoglobin > 8.0 g/dL, and platelet count > 50,000/mm3 (A1 Only)
Ethical / Other
Exclusion Criteria:
Disease Related
Concurrent Conditions
Ethical / Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: carfilzomib
Drug: carfilzomib
Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Best Overall Response Rate (ORR)
For both A0 and A1, to evaluate the best overall response rate (stringent complete response \[sCR\]+ complete response \[CR\]+ very good partial response \[VGPR\]+ partial response \[PR\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy
Time frame: A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.
Clinical Benefit Response (CBR) (A0 Only)
sCR, CR, VGPR, PR, and minimal response (MR)
Time frame: Response assessments same as described in primary outcome measure
Clinical Benefit Response (CBR) (A1 Only)
sCR, CR, VGPR, PR, and minimal response (MR)
Time frame: Response assessments same as described in primary outcome measure
Duration of Response (A0 Only)
Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
Time frame: Response assessments same as described in primary outcome measure
Duration of Response (A1 Only)
Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
Time frame: Response assessments same as described in primary outcome measure
Time to Progression (A0 Only)
Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.
Time frame: Response assessments same as described in primary outcome measure
Time to Progression (A1 Only)
Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.
Time frame: Response assessments same as described in primary outcome measure
Progression-free Survival (A0 Only)
The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.
Time frame: Response assessments same as described in primary outcome measure
Progression-free Survival (A1 Only)
The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.
Time frame: Response assessments same as described in primary outcome measure
Overall Survival (A1 Only)
The time from start of treatment to death due to any cause OS was to be censored on the date the subject was last known to be alive for those who were alive or lost to follow-up as of a data analysis cutoff date.
Time frame: Patients were to be followed by telephone contact for disease progression and OS every 3 months after study discontinuation for the first year and every 6 months thereafter for up to 2 years
Results of this study are reported in 2 parts, depending on whether a patient was enrolled and treated under the original protocol (referred to as 'A0') or under Amendment 1 and subsequent amendments (referred to as 'A1').
| Milestone | Carfilzomib (A0) | Carfilzomib (A1) |
|---|---|---|
| Started | 46 | 266 |
| Completed | 4 | 40 |
| Not completed | 42 | 226 |
| Withdrew: Adverse event | 13 | 33 |
| Withdrew: Withdrawal by subject | 2 | 22 |
| Withdrew: Progressive disease | 23 | 157 |
| Withdrew: Various reasons | 4 | 14 |
For both A0 and A1, to evaluate the best overall response rate (stringent complete response \[sCR\]+ complete response \[CR\]+ very good partial response \[VGPR\]+ partial response \[PR\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy
| % of participants w/ PR or better | Carfilzomib (A0) | Carfilzomib (A1) |
|---|---|---|
| Best Overall Response Rate (ORR) | 16.7 (6.97 to 31.36) | 23.7 (18.67 to 29.42) |
sCR, CR, VGPR, PR, and minimal response (MR)
| participants | Carfilzomib (A0) |
|---|---|
| Clinical Benefit Response (sCR+CR+VGPR+PR+MR) | 10 |
| Complete Response | 0 |
| Very Good Partial Response | 0 |
| Partial Response | 7 |
| Minimal Response | 3 |
sCR, CR, VGPR, PR, and minimal response (MR)
| participants | Carfilzomib (A1) |
|---|---|
| Clinical Benefit Response (sCR+CR+VGPR+PR+MR) | 95 |
| Complete Response | 1 |
| Very Good Partial Response | 13 |
| Partial Response | 47 |
| Minimal Response | 34 |
Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
| days | Carfilzomib (A0) for (ORR) |
|---|---|
| Duration of Response (A0 Only) | 219 (57 to NA) |
Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.
| months | Carfilzomib (A1) for (ORR) | Carfilzomib (A1) for (CBR) |
|---|---|---|
| Duration of Response (A1 Only) | 7.8 (5.6 to 9.2) | 8.3 (6.5 to 9.7) |
Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.
| months | Carfilzomib (A0) |
|---|---|
| Time to Progression (A0 Only) | 3.5 (2.4 to 6.7) |
Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.
| months | Carfilzomib (A1) |
|---|---|
| Time to Progression (A1 Only) | 3.9 (2.8 to 4.8) |
The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.
| months | Carfilzomib (A0) |
|---|---|
| Progression-free Survival (A0 Only) | 3.5 (2.4 to 6.7) |
The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.
| months | Carfilzomib (A1) |
|---|---|
| Progression-free Survival (A1 Only) | 3.7 (2.8 to 4.6) |
The time from start of treatment to death due to any cause OS was to be censored on the date the subject was last known to be alive for those who were alive or lost to follow-up as of a data analysis cutoff date.
| months | Carfilzomib (A1) - Safety Population | Carfilzomib (A1) - Response-evaluable Population |
|---|---|---|
| Overall Survival (A1 Only) | 15.4 (12.5 to 19.0) | 15.6 (13.0 to 19.2) |
Collected over All adverse events (AEs) should be reported from the time the subject signs consent through 30 days post-last dose of study drug or initiation of a new anti-cancer therapy, whichever occurs first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carfilzomib (A0) | — | 20/46 (43.5%) | 46/46 (100%) |
| Carfilzomib (A1) | — | 126/266 (47.4%) | 266/266 (100%) |
| Event | Carfilzomib (A0) | Carfilzomib (A1) |
|---|---|---|
| Disease progressionGeneral disorders | 5/46 | 16/266 |
| PneumoniaInfections and infestations | 5/46 | 23/266 |
| Renal failure acuteRenal and urinary disorders | 4/46 | 9/266 |
| Cardiac failure congestiveCardiac disorders | 2/46 | 8/266 |
| BacteraemiaInfections and infestations | 2/46 | 1/266 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/46 | 6/266 |
| Tumour lysis syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/46 | 0/266 |
| PyrexiaGeneral disorders | 1/46 | 8/266 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 1/46 | 8/266 |
| Spinal cord compressionNervous system disorders | 0/46 | 6/266 |
| Event | Carfilzomib (A0) | Carfilzomib (A1) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 34/46 | 122/266 |
| FatigueGeneral disorders | 32/46 | 130/266 |
| ThrombocytopeniaBlood and lymphatic system disorders | 23/46 | 103/266 |
| NauseaGastrointestinal disorders | 16/46 | 119/266 |
| Upper respiratory tract infectionInfections and infestations | 17/46 | 71/266 |
| LymphopeniaBlood and lymphatic system disorders | 16/46 | 62/266 |
| Blood creatinine increasedInvestigations | 16/46 | 67/266 |
| HypocalcaemiaMetabolism and nutrition disorders | 16/46 | 14/266 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/46 | 90/266 |
| DiarrhoeaGastrointestinal disorders | 15/46 | 86/266 |
Safety population: The safety population consists of all enrolled patients who received at least 1 dose of carfilzomib.
| Age, Categorical(Participants) | Carfilzomib (A0) | Carfilzomib (A1) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 146 | 172 |
| >=65 years | 20 | 120 | 140 |
| Sex: Female, Male(Participants) | Carfilzomib (A0) | Carfilzomib (A1) | Total |
|---|---|---|---|
| Female | 21 | 111 | 132 |
| Male | 25 | 155 | 180 |
The record gives a start of Aug 2007, a primary completion of Nov 2010 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib